Moreover, type 3 diabetes has recently been described, in which it is proposed that neural resistance to insulin would be at the origin of Alzheimer’s disease, so ranolazine could also be a drug to be considered in the preventive treatment of Alzheimer’s disease. This evidence concerns the gene INS and early-onset autosomal dominant Alzheimer disease.